Search
Research
Effectiveness of trivalent flu vaccine in healthy young childrenThis paper reports some of the findings from the Western Australian Influenza Vaccine Effectiveness Study, commenced in 2008, to evaluate a program providing...
Research
Diversity of Nontypeable Haemophilus influenzae strains colonizing Australian Aboriginal and non-Aboriginal childrenNontypeable Haemophilus influenzae (NTHI) strains are responsible for respiratory-related infections which cause a significant burden of disease in...
Research
Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA Randomized Trial): An unexpected observationThese findings may help to explain the decrease in external GW diagnoses seen in England.
Research
A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adultsNo currently licensed and available vaccine has been shown to provide broad protection against endemic MnB disease.
Research
Virus detection and its association with symptoms during influenza-like illness in a sample of healthy adults enrolled in a randomised controlled vaccine trialViral respiratory infections are associated with significant morbidity and mortality.
Research
Use of data linkage to investigate the aetiology of acute lower respiratory infection hospitalisations in childrenThe aim was to document the aetiology of acute lower respiratory infection (ALRI) hospitalisations in Western Australian children
Research
Toll-like receptor 7 and 8 polymorphisms: associations with functional effects and cellular and antibody responses to measles virus and vaccineSuccessful defence against viral pathogens requires the rapid recognition of virus-specific "danger signals" and the activation of both innate and adaptive...
Research
Preterm infants have deficient monocyte and lymphocyte cytokine responses to group B streptococcusGroup B streptococcus (GBS) is an important cause of early- and late-onset sepsis in the newborn. Preterm infants have markedly increased susceptibility...
Research
Estimating the impact of Western Australia's first respiratory syncytial virus immunisation program for all infants: A mathematical modelling studyThe Australian Therapeutic Goods Administration approved the use of nirsevimab, a long-acting monoclonal antibody for the prevention of Respiratory Syncytial Virus (RSV), in November 2023. Western Australia (WA) implemented a combination of nirsevimab administration strategies designed to protect all infants starting in April 2024, before the epidemic season. We developed a dynamic transmission model to predict the impact of WA's RSV immunisation program on infant hospitalisations.
Research
OPTIMUM: OPTimising IMmunisation Using Mixed schedulesPat Peter Susan Tom Jennifer Holt Richmond Prescott Snelling Kent PhD, DSc, FRCPath, FRCPI, FAA MBBS MRCP(UK) FRACP MBBS BMedSci PhD FRACP BMBS DTMH